Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr;44(4):266-275.
doi: 10.1016/j.it.2023.02.002. Epub 2023 Mar 1.

Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity

Affiliations
Free article
Review

Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity

Richard M Ransohoff. Trends Immunol. 2023 Apr.
Free article

Abstract

The emphasis on mechanisms driving multiple sclerosis (MS) symptomatic worsening suggests that we move beyond categorical clinical classifiers such as relapsing-remitting MS (RR-MS) and progressive MS (P-MS). Here, we focus on the clinical phenomenon progression independent of relapse activity (PIRA), which begins early in the disease course. PIRA occurs throughout MS, becoming more phenotypically evident as patients age. The underlying mechanisms for PIRA include chronic-active demyelinating lesions (CALs), subpial cortical demyelination, and nerve fiber injury following demyelination. We propose that much of the tissue injury associated with PIRA is driven by autonomous meningeal lymphoid aggregates, present before disease onset and unresponsive to current therapeutics. Recently, specialized magnetic resonance imaging (MRI) has identified and characterized CALs as paramagnetic rim lesions in humans, enabling novel radiographic-biomarker-clinical correlations to further understand and treat PIRA.

Keywords: aging; imaging; inflammation; lymphoid aggregates; meninges; multiple sclerosis; neurodegeneration; progression.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.R. is interim Chief Medical Officer and scientific Co-Founder of Abata Therapeutics, which is developing treatments for autoimmune conditions including progressive MS.

MeSH terms